In addition, Palmen MJ et al. showed that anti-MAC-1 monoclonal antibodies not only reduced myeloid cell tissue infiltration and inflammation but also decreased the recruitment of MDSCs into the tumor site [129]. This evidence concerns the gene ITGAM and neoplasm.